| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 6,960 | 7,925 | 7,769 | 7,082 |
| Cost of goods sold | 1,445 | 1,624 | 1,569 | 1,501 |
| Research and development expenses | 1,372 | 1,583 | 1,346 | 1,491 |
| Acquired in-process research and development expenses | 107 | 540 | 170 | 61 |
| In-process research and development impairments | NaN | 400 | 0 | 190 |
| Selling, general and administrative expenses | 1,451 | 1,794 | 1,357 | 1,365 |
| Total costs and expenses | 4,374 | 5,941 | 4,442 | 4,608 |
| Operating income | 2,586 | 1,984 | 3,327 | 2,474 |
| Interest expense | 240 | 254 | 256 | 254 |
| Other (income) expense, net | 235 | 349 | 569 | 208 |
| Income before income taxes | 2,580 | 2,077 | 3,641 | 2,429 |
| Income tax expense at u.s. federal statutory tax rate | NaN | 88* | NaN | NaN |
| State taxes, net of federal benefit | NaN | -34* | NaN | NaN |
| Tax rate differential-IE | NaN | -29* | NaN | NaN |
| Other-IE | NaN | 0* | NaN | NaN |
| Tax rate differential-Foreign Tax Jurisdiction Other | NaN | -2* | NaN | NaN |
| Global intangible low-taxed income | NaN | 21* | NaN | NaN |
| Foreign-derived intangible income | NaN | 21* | NaN | NaN |
| U.s. taxation of foreign branches | NaN | 2* | NaN | NaN |
| Other | NaN | 1* | NaN | NaN |
| R&d tax credits | NaN | 36* | NaN | NaN |
| Other | NaN | 2* | NaN | NaN |
| Valuation allowance-US | NaN | -134* | NaN | NaN |
| Acquired ipr&d and related charges | NaN | 16* | NaN | NaN |
| Other | NaN | 5* | NaN | NaN |
| Changes in unrecognized tax benefits | NaN | 15* | NaN | NaN |
| Settlement of tax examinations | NaN | 0* | NaN | NaN |
| Legal entity restructuring | NaN | 0* | NaN | NaN |
| Other-US | NaN | 7* | NaN | NaN |
| Income tax expense | 559 | -105 | 589 | 468 |
| Net income | NaN | 2,183 | 3,052 | 1,960 |
| Net loss attributable to noncontrolling interest | NaN | 0 | 0 | 0 |
| Net income | 2,021 | 2,183 | 3,052 | 1,960 |
| Basic EPS | 1.63 | 1.758 | 2.46 | 1.57 |
| Diluted EPS | 1.61 | 1.744 | 2.43 | 1.56 |
| Basic Average Shares | 1,242,000,000 | 1,242,000,000 | 1,243,000,000 | 1,245,000,000 |
| Diluted Average Shares | 1,254,000,000 | 1,252,000,000 | 1,254,000,000 | 1,255,000,000 |
GILEAD SCIENCES, INC. (GILD)
GILEAD SCIENCES, INC. (GILD)